Lipid-altering agents: the future

Author: A.S. Wierzbicki¹

Source: International Journal of Clinical Practice, Volume 58, Number 11, November 2004 , pp. 1063-1072(10)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Summary

Lipid-lowering is established as proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development. It also discusses other therapeutic targets, such as squalene synthase, microsomal transfer protein, acyl-cholesterol acyl transferase, cholesterol ester transfer protein, peroxosimal proliferator-activating receptors and lipoprotein (a), for which compounds have been developed and have at least reached trials in animal models. Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.

Keywords: Cholesterol; risk factor; HDL; LDL; therapy; treatment

Document Type: Research article

DOI: 10.1111/j.1742-1241.2004.00087.x

Affiliations: 1: St. Thomas' Hospital Campus, Lambeth Palace Road, London, UK

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy